Toxic Ig light chains secreted by neoplastic plasma cells, and the fibrillar deposits they form cause light chain (AL) amyloidosis. Current treatments for AL target the neoplastic plasma cells in order to eliminate light chain production, stop and possibly reverse organ damage. Depth of hematologic response is thus a surrogate marker for survival. 1 Only 25% of newly diagnosed AL patients have sufficient organ reserve to be considered eligible for stem cell transplantation (SCT). In a recent report, bortezomibbased initial therapy for AL patients ineligible for SCT reduced light chain production and reversed organ damage sufficiently enough to enable 33% to become eligible for SCT. 2 As this series indicated, the treatment of AL patients has dramatically improved with bortezomib-based therapy and the rapid deep hematologic responses it effects. Hematologic response rates of 62% have been reported in a large series with 43% of patients achieving very good partial (VGPR) or complete responses (CR).
3 Not all centers offer SCT for AL and, given the efficacy of bortezomib-based initial therapy, not all AL patients opt for SCT at diagnosis even if they are eligible.
We report a series of patients (N = 12) with biopsy-proven AL amyloidosis who had less than a very good partial response (PR) to bortezomib-based initial therapy (nine had no response (NR) and three PR), and therefore were likely to have inferior overall survival, 1 who then underwent SCT with risk-adapted melphalan. The median age was 58 (range, 53-70) and 9 were male. Ten came to us after being treated elsewhere; they did not receive SCT as first-line treatment because of plasma cells 410%, institutional limitations or poor performance status. Two patients diagnosed at our center as eligible for SCT refused our recommendation and chose bortezomib-based therapy instead. Nine patients were treated with bortezomib, cyclophosphamide and dexamethasone, and 3 with bortezomib and dexamethasone, for a median of 4 cycles (2-8). Patients receiving 2 or 3 cycles were switched to SCT because of the risk of organ disease progression due to ineffective therapy as is standard practice. 4 Ten patients (83%) had lambda clonal disease. Nine with NR had median involved FLC at diagnosis and post initial therapy (pre-SCT) of 180 (74-648) and 265 mg/L (116-410), while 3 with PR had medians of 2552 (250-9780) and 100 mg/L (98-1620) at those time points respectively. In neither instance were comparisons statistically significant by paired t-test. Six had two organs and six had one organ involved. Seven had cardiac involvement, six stage 2 and one stage 3. Seven had renal involvement, one stage 1, four stage 2 and two stage 3. Two had gastrointestinal involvement.
All patients were mobilized with G-CSF and plerixafor as previously described 5 prior to risk-adapted melphalan and SCT. 6 All patients had their pre-and post-SCT hematologic and organ responses evaluated at 2-3 months post-SCT. Hematologic, cardiac and renal responses were assessed by standard criteria. 7, 8 Overall survival was evaluated by Kaplan-Meier. Although risk-adapted melphalan-based SCT has been used as treatment for AL amyloidosis with an excellent safety profile and efficacy, 9 the use of SCT as second-line therapy for patients with suboptimal responses to bortezomib has not been formally described. SCT and bortezomib-based initial therapy have not been compared in a randomized manner. Both produce deep hematologic responses, but SCT has historically produced durable hematologic and organ responses. 3, 10 The durability of remissions to bortezomib-based therapy is less well understood due to its recent use in this disease. Nonetheless, bortezomib-based therapy is now commonly used as front-line treatment in lieu of SCT for reasons such as plasma cell infiltration 410% and patient preference; if patients do not respond, however, no standard second-line therapy is established, although we know that patients with PR or NR have poorer overall survival. We also know that the use of the immunomodulatory agent lenalidomide in combination with dexamethasone or with cyclophosphamide and dexamethasone carries risks of cardiac and renal toxicity in this population of patients and at best a ⩾ VGPR rate of 40%. 3, 11, 12 This study evaluated the outcomes of patients with suboptimal response to bortezomib-based initial therapy who then underwent SCT and confirms that risk-adapted melphalan-based SCT can be a safe and effective second-line option that yields deep hematologic responses with 42% of patients achieving CR. For patients who Abbreviations: CR = complete response; NR = no response; PR = partial response; SCT = stem cell transplantarion; VGPR = very good partial response.
achieve hematologic CR, 5-year OS is 70% irrespective of treatment modality. 13 Of note, the median dose of melphalan in this cohort was 140 mg/m 2 , raising a concern regarding efficacy related to melphalan dosing; however, the aggregate data on SCT for AL from the IBMTR indicate that, in the modern era 2007-2012, hematologic response rates were higher and relapse rates lower than in the period 2001-2006 despite a drop in the median dose of melphalan from 175 to 143 mg/m 2 , results consistent with those of a singlecenter series showing that in multivariate analysis both event-free and OS were not significantly affected by melphalan dose in 143 patients who underwent risk-adapted melphalan SCT with post-SCT consolidation. 9, 14 Cytogenetic and FISH data for the clonal plasma cell disease at diagnosis were not available for the 12 patients whose outcomes we report. A possible explanation for the hematologic responses to SCT after suboptimal responses to bortezomib may be the influence of genetic aberrations on the susceptibility of the plasma cell clone. Patients with t(11;14) respond more frequently to melphalan-based than to bortezomib-based therapy. 15 Whether prior treatment with bortezomib in such cases enhances clonal plasma cell susceptibility to melphalan is unknown. Nevertheless, selected patients who have suboptimal responses to first-line bortezomib therapy may be effectively treated with risk-adapted melphalan-based SCT. 
